Does Semaglutide Affect Your Hormones? Separating Fact from Worry

The common worry: does Wegovy mess with your sex hormones or thyroid?

The single biggest misconception our prescribers hear is that semaglutide is some kind of hormonal treatment, like HRT or a thyroid drug, and that taking it will send your body's endocrine system into disarray. That is not what the evidence shows. Semaglutide belongs to a class called GLP-1 receptor agonists, it binds to receptors that respond to glucagon-like peptide-1, a hormone your gut releases naturally every time you eat. By staying bound to those receptors longer than your own GLP-1 would, it prolongs the signal: appetite falls, insulin rises proportionally to food intake, and your stomach empties more slowly.

What it does not do, directly, is touch oestrogen, progesterone, testosterone, cortisol or your thyroid hormones. Clinical trials involving thousands of adults found no mechanistic reason to expect direct sex-hormone disruption from the drug itself. The NHS medicines information for semaglutide does not list hormonal imbalance as a recognised side effect, and endocrine monitoring is not routinely required during treatment. If you are wondering whether Wegovy contains hormones of its own, that question has its own dedicated page. If you want a fuller picture of which hormone Wegovy actually contains, that question has its own dedicated page.

The nuance worth holding onto: significant weight loss (of any kind) can itself alter hormone levels. Oestrogen is partly produced in adipose tissue, so as body composition changes, oestrogen activity can shift modestly. This is not an effect of semaglutide specifically; it is an effect of losing weight. Clinically, that distinction matters, and it is worth discussing with your prescriber if it affects a condition you are managing.

What hormones does semaglutide directly influence, and how?

The hormonal effects that are documented and well-understood are metabolic rather than reproductive. Semaglutide amplifies insulin secretion in a glucose-dependent way: it only prompts insulin release when blood sugar is actually rising, which is why the risk of hypoglycaemia in people without diabetes is low compared with some older treatments. It also suppresses glucagon (a counter-regulatory hormone that signals the liver to release stored glucose) which contributes to steadier blood sugar levels after meals.

Appetite itself has a hormonal dimension. GLP-1 signals to the hypothalamus, the part of the brain that governs hunger and satiety. By sustaining that signal, semaglutide effectively tells the brain that the meal is still being processed, which is why many people find their desire to eat reduces considerably. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks and documented an average weight reduction of around 15% at the 2.4mg dose, a result driven substantially by this appetite-hormone pathway, not by any change to sex or stress hormones.

There is also an effect on gastric emptying. Food moves more slowly from the stomach into the small intestine. That is relevant not just for appetite but for drug absorption, which brings us to the practical questions that matter most for people already on other treatments. You can explore how this relates to what semaglutide does to blood work more broadly, including the metabolic markers that prescribers track.

Oral contraceptives, HRT and the absorption question

This is where the hormonal question becomes practically important for a lot of people. Semaglutide slows gastric emptying, and slower gastric emptying can reduce the peak concentration of medicines that are absorbed in the upper gut, including some oral drugs. The clinical guidance distinguishes between the two injectable GLP-1 medicines available for weight management in the UK. For tirzepatide (Mounjaro), NHS guidance specifically advises adding a non-oral contraceptive method during the first four weeks and after each dose increase; for semaglutide, the same evidence of reduced pill effectiveness has not been established in the same way.

HRT is a related area. NHS England's guidance on weight-management injections suggests considering transdermal HRT (patches or gels) rather than oral HRT while on tirzepatide, for the same absorption reason. Again, the published concern centres on tirzepatide rather than semaglutide specifically, but it illustrates why your complete medication list matters at consultation. If you are currently on oral HRT or an oral contraceptive and considering Wegovy, it is a conversation to have openly with a prescriber, not something to guess at. The NHS England wraparound care guidance for weight-management injections covers this directly and is worth reading.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber who goes through your current medicines as part of the standard assessment, not a checklist run by software. If something in your medication history needs clarifying, that happens before any prescription is issued. For anyone curious about a related angle, there is also a page on whether Wegovy disrupts hormones more broadly that covers patient-reported experience alongside the clinical picture.

Sleep, cycles and the indirect effects worth knowing about

Two questions come up regularly alongside the main hormone query. One is whether semaglutide affects sleep, the short answer is that it is not a direct pharmacological effect, though GI side effects like nausea or reflux, especially in the early weeks, can disturb sleep in some people. There is a fuller look at this on the semaglutide and sleep page. The other is menstrual cycle changes. Some people notice cycle irregularities after starting treatment, but the evidence points to weight loss itself as the driver rather than a direct hormonal action of semaglutide. Significant, rapid weight change is a known influence on cycle regularity in people with certain underlying conditions, such as polycystic ovary syndrome.

The STRIDE study explored cardiovascular and metabolic outcomes with semaglutide in more detail, adding to the body of evidence about what this medicine does and does not change at a systemic level. For most people, the hormonal picture with semaglutide is more reassuring than they expected going in. The effects are targeted and metabolic; the broader endocrine system is not being overridden. That said, if you are managing a hormone-sensitive condition, telling your prescriber upfront is the practical step that keeps treatment safe.

If you would like to understand your options for weight management, including which treatments are currently available and how the process works, the free consultation page is the place to start. There is no pressure and no commitment, a prescriber looks at your situation and gives you a considered answer.